501 related articles for article (PubMed ID: 25000966)
21. LRRK2-mediated neurodegeneration and dysfunction of dopaminergic neurons in a Caenorhabditis elegans model of Parkinson's disease.
Yao C; El Khoury R; Wang W; Byrd TA; Pehek EA; Thacker C; Zhu X; Smith MA; Wilson-Delfosse AL; Chen SG
Neurobiol Dis; 2010 Oct; 40(1):73-81. PubMed ID: 20382224
[TBL] [Abstract][Full Text] [Related]
22. The prodromal phase of leucine-rich repeat kinase 2-associated Parkinson disease: Clinical and imaging Studies.
Pont-Sunyer C; Tolosa E; Caspell-Garcia C; Coffey C; Alcalay RN; Chan P; Duda JE; Facheris M; Fernández-Santiago R; Marek K; Lomeña F; Marras C; Mondragon E; Saunders-Pullman R; Waro B;
Mov Disord; 2017 May; 32(5):726-738. PubMed ID: 28370517
[TBL] [Abstract][Full Text] [Related]
23. Prospective clinical and DaT-SPECT imaging in premotor
Sierra M; Martínez-Rodríguez I; Sánchez-Juan P; González-Aramburu I; Jiménez-Alonso M; Sánchez-Rodríguez A; Berciano J; Banzo I; Infante J
Neurology; 2017 Aug; 89(5):439-444. PubMed ID: 28679601
[TBL] [Abstract][Full Text] [Related]
24. Altered Development of Synapse Structure and Function in Striatum Caused by Parkinson's Disease-Linked LRRK2-G2019S Mutation.
Matikainen-Ankney BA; Kezunovic N; Mesias RE; Tian Y; Williams FM; Huntley GW; Benson DL
J Neurosci; 2016 Jul; 36(27):7128-41. PubMed ID: 27383589
[TBL] [Abstract][Full Text] [Related]
25. Fall risk and gait in Parkinson's disease: the role of the LRRK2 G2019S mutation.
Mirelman A; Heman T; Yasinovsky K; Thaler A; Gurevich T; Marder K; Bressman S; Bar-Shira A; Orr-Urtreger A; Giladi N; Hausdorff JM;
Mov Disord; 2013 Oct; 28(12):1683-90. PubMed ID: 24123150
[TBL] [Abstract][Full Text] [Related]
26. Dopamine D2 receptor activation potently inhibits striatal glutamatergic transmission in a G2019S LRRK2 genetic model of Parkinson's disease.
Tozzi A; Durante V; Bastioli G; Mazzocchetti P; Novello S; Mechelli A; Morari M; Costa C; Mancini A; Di Filippo M; Calabresi P
Neurobiol Dis; 2018 Oct; 118():1-8. PubMed ID: 29908325
[TBL] [Abstract][Full Text] [Related]
27. Dopaminergic neurodegeneration induced by Parkinson's disease-linked G2019S LRRK2 is dependent on kinase and GTPase activity.
Nguyen APT; Tsika E; Kelly K; Levine N; Chen X; West AB; Boularand S; Barneoud P; Moore DJ
Proc Natl Acad Sci U S A; 2020 Jul; 117(29):17296-17307. PubMed ID: 32631998
[TBL] [Abstract][Full Text] [Related]
28. Dyskinesias in patients with Parkinson's disease: effect of the leucine-rich repeat kinase 2 (LRRK2) G2019S mutation.
Yahalom G; Kaplan N; Vituri A; Cohen OS; Inzelberg R; Kozlova E; Korczyn AD; Rosset S; Friedman E; Hassin-Baer S
Parkinsonism Relat Disord; 2012 Nov; 18(9):1039-41. PubMed ID: 22703868
[TBL] [Abstract][Full Text] [Related]
29. Impaired dopaminergic neurotransmission and microtubule-associated protein tau alterations in human LRRK2 transgenic mice.
Melrose HL; Dächsel JC; Behrouz B; Lincoln SJ; Yue M; Hinkle KM; Kent CB; Korvatska E; Taylor JP; Witten L; Liang YQ; Beevers JE; Boules M; Dugger BN; Serna VA; Gaukhman A; Yu X; Castanedes-Casey M; Braithwaite AT; Ogholikhan S; Yu N; Bass D; Tyndall G; Schellenberg GD; Dickson DW; Janus C; Farrer MJ
Neurobiol Dis; 2010 Dec; 40(3):503-17. PubMed ID: 20659558
[TBL] [Abstract][Full Text] [Related]
30. Lrrk2 and alpha-synuclein are co-regulated in rodent striatum.
Westerlund M; Ran C; Borgkvist A; Sterky FH; Lindqvist E; Lundströmer K; Pernold K; Brené S; Kallunki P; Fisone G; Olson L; Galter D
Mol Cell Neurosci; 2008 Dec; 39(4):586-91. PubMed ID: 18790059
[TBL] [Abstract][Full Text] [Related]
31. Dopamine turnover increases in asymptomatic LRRK2 mutations carriers.
Sossi V; de la Fuente-Fernández R; Nandhagopal R; Schulzer M; McKenzie J; Ruth TJ; Aasly JO; Farrer MJ; Wszolek ZK; Stoessl JA
Mov Disord; 2010 Dec; 25(16):2717-23. PubMed ID: 20939082
[TBL] [Abstract][Full Text] [Related]
32. The C-terminal domain of LRRK2 with the G2019S mutation is sufficient to produce neurodegeneration of dopaminergic neurons in vivo.
Cresto N; Gaillard MC; Gardier C; Gubinelli F; Diguet E; Bellet D; Legroux L; Mitja J; Auregan G; Guillermier M; Josephine C; Jan C; Dufour N; Joliot A; Hantraye P; Bonvento G; Déglon N; Bemelmans AP; Cambon K; Liot G; Brouillet E
Neurobiol Dis; 2020 Feb; 134():104614. PubMed ID: 31605779
[TBL] [Abstract][Full Text] [Related]
33. The role of tyrosine hydroxylase-dopamine pathway in Parkinson's disease pathogenesis.
Zhou ZD; Saw WT; Ho PGH; Zhang ZW; Zeng L; Chang YY; Sun AXY; Ma DR; Wang HY; Zhou L; Lim KL; Tan EK
Cell Mol Life Sci; 2022 Nov; 79(12):599. PubMed ID: 36409355
[TBL] [Abstract][Full Text] [Related]
34. Age- and Sex-Dependent Behavioral and Neurochemical Alterations in hLRRK2-G2019S BAC Mice.
Yao N; Skiteva O; Chergui K
Biomolecules; 2022 Dec; 13(1):. PubMed ID: 36671436
[TBL] [Abstract][Full Text] [Related]
35. The Parkinson's Disease-Associated Mutation LRRK2-G2019S Impairs Synaptic Plasticity in Mouse Hippocampus.
Sweet ES; Saunier-Rebori B; Yue Z; Blitzer RD
J Neurosci; 2015 Aug; 35(32):11190-5. PubMed ID: 26269629
[TBL] [Abstract][Full Text] [Related]
36. No dopamine cell loss or changes in cytoskeleton function in transgenic mice expressing physiological levels of wild type or G2019S mutant LRRK2 and in human fibroblasts.
Garcia-Miralles M; Coomaraswamy J; Häbig K; Herzig MC; Funk N; Gillardon F; Maisel M; Jucker M; Gasser T; Galter D; Biskup S
PLoS One; 2015; 10(4):e0118947. PubMed ID: 25830304
[TBL] [Abstract][Full Text] [Related]
37. Lack of exacerbation of neurodegeneration in a double transgenic mouse model of mutant LRRK2 and tau.
Mikhail F; Calingasan N; Parolari L; Subramanian A; Yang L; Flint Beal M
Hum Mol Genet; 2015 Jun; 24(12):3545-56. PubMed ID: 25804954
[TBL] [Abstract][Full Text] [Related]
38. Phosphorylation of amyloid precursor protein by mutant LRRK2 promotes AICD activity and neurotoxicity in Parkinson's disease.
Chen ZC; Zhang W; Chua LL; Chai C; Li R; Lin L; Cao Z; Angeles DC; Stanton LW; Peng JH; Zhou ZD; Lim KL; Zeng L; Tan EK
Sci Signal; 2017 Jul; 10(488):. PubMed ID: 28720718
[TBL] [Abstract][Full Text] [Related]
39. Diapocynin prevents early Parkinson's disease symptoms in the leucine-rich repeat kinase 2 (LRRK2R¹⁴⁴¹G) transgenic mouse.
Dranka BP; Gifford A; Ghosh A; Zielonka J; Joseph J; Kanthasamy AG; Kalyanaraman B
Neurosci Lett; 2013 Aug; 549():57-62. PubMed ID: 23721786
[TBL] [Abstract][Full Text] [Related]
40. Neuropsychological performance in LRRK2 G2019S carriers with Parkinson's disease.
Alcalay RN; Mejia-Santana H; Mirelman A; Saunders-Pullman R; Raymond D; Palmese C; Caccappolo E; Ozelius L; Orr-Urtreger A; Clark L; Giladi N; Bressman S; Marder K;
Parkinsonism Relat Disord; 2015 Feb; 21(2):106-10. PubMed ID: 25434972
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]